Clostridium difficile Infections Disease Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Clostridium difficile Infections Disease Pipeline Drugs Assessment Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2019 - 2030

Clostridium difficile is a bacterium that infects the bowel and caused diarrhea. This infection is most commonly seen in people who were recently been treated with antibiotics and it can be spread easily to others. Clostridium difficile is also called as C. difficile or C.diff. C. diff infections may cause serious bowel problems. Symptoms of C.diff infections includes watery diarrhea, painful cramps in tummy, dehydration, dry mouth, head ache, loss of weight and appetite, etc. C.diff can be diagnosed by enzyme immunoassay, polymerase chain reaction, GDH or EIA. Treatment for Clostridium difficile infection includes antibiotic course.

Clostridium Difficile Infections disease Pipeline Drugs Assessment Key Developments:

  • In July 2016, Valneva SE completed Phase II study for its prophylactic vaccine candidate VLA84 targeting primary prevention of  difficile infection (CDI). The study met its primary endpoint in terms of identifying the dose/formulation with the highest seroconversion rate against both toxins A and B and confirmed the favorable safety profile observed in Phase
  • In June 2017, Seres Therapeutics, Inc. initiated Phase 3 clinical study of its SER-109 (ECOSPOR III) in patients with multiply recurrent  difficile infection and also commenced Phase 1b clinical trial evaluating SER-262 in patients with primary Clostridium difficile infection (CDI).
  • On May 11, 2017 The U.S. Food and Drug Administration (FDA) granted a Breakthrough Therapy Designation for SYN-004 (ribaxamase) of Synthetic Biologicsfor the prevention of Clostridium difficile infection.
  • In October 2015, RBX2660 of Rebiotix was grated orphan drug status and fast track designation from U.S.FDA for its potential to prevent recurrent C. diff. infection.

 

Clostridium difficile Infections Disease Pipeline Drugs Assessment Dynamics

Clostridium difficile Infections Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Clostridium difficile Infections treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Clostridium difficile Infections disease pipeline drugs development. This report studies the dynamics of the Clostridium difficile Infections Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Clostridium difficile Infections disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Clostridium Difficile Infections disease Pipeline Drugs Assessment Segmentation Analysis

Report Benchmarks

Details

By Trial Phase

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company

  • Synthetic Biologics
  • Da Volterra
  • Pfizer Inc.
  • Valneva SE
  • Seres Therapeutics
  • Summit Therapeutics
  • Rebiotix Inc.
  • CRESTOVO
  • Merck
  • XBiotech
  • Others

By Drugs

  • Vancomycin
  • Fidaxomicin
  • Metronidazole
  • Ridinilazole
  • Cadazolid
  • Bezlotoxumab
  • Others

By Type

  • Systemic JIA
  • Oligoarthritis
  • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
  • Psoriatic arthritis
  • Enthesitis-related arthritis
  • Undifferentiated arthritis

By Route of Administration

  • Oral
  • Parenteral

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis

Download Free Sample Report

Frequently Asked Questions

2023 is the base year and 2030 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

 

  1. Executive Summary
  2. Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Introduction
    • Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Taxonomy
    • Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Definitions
      • Trial Phase
      • Drugs
      • Type of Condition
      • Route of Administration
  1. Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Dynamic Factors - Impact Analysis
    • Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Competition Landscape
    • Epidemiology
  2. Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
    • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market OpportunityAnalysis
  3. Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market, By Trial Phase, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Preclinical Trials
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 1
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 2
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 3
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Phase 4
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Forecast, By Drugs,2019 - 2023 and Forecast, 2024 - 2030
    • Vancomycin
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Fidaxomicin
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Metronidazole
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Ridinilazole
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Cadazolid
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Bezlotoxumab
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Forecast, By Type of Condition, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Systemic JIA
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Oligoarthritis
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Psoriatic arthritis
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Enthesitis-related arthritis
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Undifferentiated arthritis
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Forecast, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Oral
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Parenteral
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • North America
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Clostridium difficile Infections Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Rote of Administration and Region, 2024 - 2030
  2. North America Clostridium difficile Infections Disease Pipeline Drugs Assessment MarketAnalysis,2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Vancomycin
      • Fidaxomicin
      • Metronidazole
      • Ridinilazole
      • Cadazolid
      • Bezlotoxumab
      • Others
    • Type of Condition Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Systemic JIA
      • Oligoarthritis
      • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
      • Psoriatic arthritis
      • Enthesitis-related arthritis
      • Undifferentiated arthritis
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2016 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • S.
      • Canada
    • North America Clostridium difficile Infections Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Rote of Administration and Country, 2024 - 2030
    • North America Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Dynamics Trends
  3. Europe Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Vancomycin
      • Fidaxomicin
      • Metronidazole
      • Ridinilazole
      • Cadazolid
      • Bezlotoxumab
      • Others
    • Type of Condition Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Systemic JIA
      • Oligoarthritis
      • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
      • Psoriatic arthritis
      • Enthesitis-related arthritis
      • Undifferentiated arthritis
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Clostridium difficile Infections Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Rote of Administration and Country, 2024 - 2030
    • Europe Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Dynamics Trends
  4. Asia-Pacific Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Vancomycin
      • Fidaxomicin
      • Metronidazole
      • Ridinilazole
      • Cadazolid
      • Bezlotoxumab
      • Others
    • Type of Condition Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Systemic JIA
      • Oligoarthritis
      • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
      • Psoriatic arthritis
      • Enthesitis-related arthritis
      • Undifferentiated arthritis
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Japan
      • China
      • India
      • ASEAN
      • Australia & New Zealand
      • Rest of Asia-Pacific
    • Asia-Pacific Clostridium difficile Infections Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Rote of Administration and Country, 2024 - 2030
    • Asia-Pacific Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Dynamics Trends
  5. Latin America Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Vancomycin
      • Fidaxomicin
      • Metronidazole
      • Ridinilazole
      • Cadazolid
      • Bezlotoxumab
      • Others
    • Type of Condition Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Systemic JIA
      • Oligoarthritis
      • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
      • Psoriatic arthritis
      • Enthesitis-related arthritis
      • Undifferentiated arthritis
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Clostridium difficile Infections Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Rote of Administration and Country, 2024 - 2030
    • Latin America Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Dynamics Trends
  6. Middle East and Africa Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
    • Trial Phase Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)
      • Preclinical Trials
      • Phase 1
      • Phase 2
      • Phase 3
      • Phase 4
    • Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Vancomycin
      • Fidaxomicin
      • Metronidazole
      • Ridinilazole
      • Cadazolid
      • Bezlotoxumab
      • Others
    • Type of Condition Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Systemic JIA
      • Oligoarthritis
      • Polyarticular arthritis,rheumatoid factor negative/ rheumatoid factor positive
      • Psoriatic arthritis
      • Enthesitis-related arthritis
      • Undifferentiated arthritis
    • Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Oral
      • Parenteral
    • Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Clostridium difficile Infections Disease Pipeline Drugs Assessment Market - Opportunity Analysis Index, By Trial Phase, By Drugs, By Type of Condition, By Rote of Administration and Country, 2024 - 2030
    • MEA Clostridium difficile Infections Disease Pipeline Drugs Assessment Market Dynamics Trends
  7. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Trial Phase& Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Synthetic Biologics
      • Da Volterra
      • Pfizer Inc.
      • Valneva SE
      • Seres Therapeutics
      • Summit Therapeutics
      • Rebiotix Inc.
      • CRESTOVO
      • Merck
      • XBiotech 
  1. Research Methodology
  2. Key Assumptions and Acronyms

 

Key Market Players

  • Synthetic Biologics
  • Da Volterra
  • Pfizer Inc.
  • Valneva SE
  • Seres Therapeutics
  • Summit Therapeutics
  • Rebiotix Inc.
  • CRESTOVO
  • Merck
  • XBiotech 

Related Industry Reports